AMT Medical

Executive Summary

AMT Medical is a Dutch medical device company pioneering the Elana® Anastomotic System, a novel tool designed to simplify the most complex step in coronary artery bypass graft (CABG) surgery: the anastomosis. By enabling reproducible, off-pump, and minimally invasive procedures, the system has the potential to improve patient outcomes, reduce recovery times, and expand access to surgical revascularization. The technology is also positioned to integrate with robotic-assisted platforms, aligning with the broader trend toward automation in surgery. Founded in 2003 and based in Maastricht, the company operates in the large and growing cardiac surgery market, where there is a clear unmet need for standardization and less invasive approaches. While the company is private and has not disclosed funding or valuation, its focused innovation and long development timeline suggest a disciplined approach to bringing the Elana system to market. The conviction score is 65, reflecting significant technological promise offset by the early stage of commercialization and lack of recent milestones.

Upcoming Catalysts (preview)

• Q3 2026CE Mark Approval for Elana Anastomotic System70% success
• TBDStrategic Partnership with Robotic Surgery Platform50% success
• Q1 2026First-in-Human Clinical Study Publication80% success